Arcadia Biosciences gets Nasdaq delisting notice for bid price below $1.00

Arcadia Biosciences, Inc.

Nasdaq notified Arcadia on Sept 27 that common stock failed minimum $1.00 bid price for 30 consecutive days.
Company has 180 calendar days, until March 27, 2023, to regain compliance; stock continues trading on Nasdaq Capital Market.
To cure, closing bid price must be at least $1.00 for ten consecutive business days during the grace period.
If not compliant by March 2023, may qualify for second 180-day period if it meets other listing standards and plans reverse stock split.
Arcadia is monitoring bid price and may consider options, including a reverse stock split, to regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.